Hogy Medical Co (3593) AI Stock Analysis

• Market Cap: $117.07B
• Dividend Yield: 1.61%
• Average Volume (3M): 124.93K
• Price to Earnings (P/E): 95.3
• Beta (1Y): 0.49
• Revenue Growth: -2.06%
• EPS Growth: -79.17%
• Country: JP
• Employees: 1,408
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 8.12
• Shares Outstanding: 22,535,463
• 10 Day Avg. Volume: 99,840
• 30 Day Avg. Volume: 124,930
• PEG Ratio: -1.72
• Price to Book (P/B): 1.44
• Price to Sales (P/S): 2.74
• P/FCF Ratio: 16.45
• Enterprise Value/Market Cap: 0.67
• Enterprise Value/Revenue: 2.02
• Enterprise Value/Gross Profit: 6.27
• Enterprise Value/Ebitda: 8.54
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 64 Neutral
• Price Target: ¥5,711.00 ▲(6.75% Upside)

Hogy Medical Co's overall stock score is primarily influenced by its stable financial position and positive technical indicators. However, the high P/E ratio suggests overvaluation, which is a significant concern. The lack of earnings call and corporate events data limits further insights.

Hogy Medical Co Business Overview & Revenue Model

Company Description

Hogy Medical Co.,Ltd., together with its subsidiaries, manufactures and sells medical supplies to healthcare facilities in Japan. It offers kit products for surgery applications; all-in-one kits for pre/mid/post-surgery; non-woven products, including gowns, personal protective equipment and wearables, drapes, packaged products, instrument table covers, and wraps; and Tigalyer, a multi-layer fabric. The company also provides sterilization products, such as hybrid Mekkin bags, hybrid Mekkin bags ID layered type, and autoclave forceps stand caps; Mekkin cards, which are detection cards used to judge the sterilization process when sterilizing in an autoclave; ethylene oxide gas cards that are detection cards used to judge the sterilization process when sterilizing using ethylene oxide gas; and indicator tapes for autoclave sterilization. In addition, it offers ME equipment operation management system; narcotics/poisons box, an automatic drug reading management system using radio frequency identification; and Securea, a polyurethane sponge for endoscopic surgery. The company was formerly known as Hogy Co., Ltd. and changed its name to Hogy Medical Co.,Ltd. in 1987. Hogy Medical Co.,Ltd. was founded in 1955 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Hogy Medical Co. generates revenue primarily through the sale of its medical devices and diagnostic products, which are distributed to healthcare institutions and practitioners. The company employs a multi-faceted revenue model that includes direct sales, partnerships with distributors, and long-term contracts with healthcare organizations. Key revenue streams include sales from surgical instruments, imaging technologies, and monitoring equipment. Additionally, Hogy Medical Co. may benefit from service agreements and maintenance contracts associated with its products. Strategic partnerships with healthcare providers and technology firms further enhance its market reach and drive sales growth, contributing significantly to its overall earnings.

Hogy Medical Co Financial Statement Overview

Summary

Hogy Medical Co exhibits financial stability with a solid balance sheet, low debt, and strong cash flow generation. Despite some decline in profitability margins, the company's revenue and gross margin performance remain solid, supported by low leverage and a high equity ratio.

Income Statement

Hogy Medical Co shows solid revenue stability with a slight increase in revenue over the years. The Gross Profit Margin is consistently strong, indicating effective cost management. However, there's a notable decline in Net Profit Margin and EBIT Margin in the latest year compared to prior periods, suggesting increased operational costs or lower pricing power. The EBITDA Margin remains robust, highlighting strong earnings before accounting for interest, taxes, depreciation, and amortization.

Balance Sheet

The company maintains a healthy balance sheet with a very low Debt-to-Equity Ratio, indicating low financial leverage. The Return on Equity has seen some fluctuation but remains positive, reflecting efficient use of equity capital. The Equity Ratio is high, signifying strong financing through equity and low reliance on debt, which provides financial stability.

Cash Flow

Hogy Medical Co exhibits strong cash flow with consistent Free Cash Flow generation and growth in Operating Cash Flow. The Free Cash Flow to Net Income Ratio indicates solid cash generation relative to net income, despite some variability in Free Cash Flow growth over the years. The Operating Cash Flow to Net Income Ratio showcases the company's ability to convert net income into cash effectively.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	38.79B	39.14B	39.10B	38.98B	36.78B	36.50B
Gross Profit	12.48B	12.62B	12.49B	15.74B	15.42B	15.33B
EBITDA	9.17B	8.75B	10.71B	9.84B	10.25B	10.18B
Net Income	1.25B	1.52B	2.80B	4.32B	4.37B	4.96B
Balance Sheet
Total Assets	96.10B	97.89B	100.04B	102.18B	98.97B	105.64B
Cash, Cash Equivalents and Short-Term Investments	21.64B	22.00B	19.42B	18.86B	14.36B	20.55B
Total Debt	13.17B	13.67B	5.82B	8.89B	10.00B	330.00M
Total Liabilities	22.40B	23.56B	13.92B	18.50B	18.97B	9.69B
Stockholders Equity	73.69B	74.32B	86.11B	83.61B	79.96B	95.88B
Cash Flow
Free Cash Flow	4.89B	6.53B	4.32B	7.78B	5.30B	-686.00M
Operating Cash Flow	9.47B	11.76B	7.12B	9.18B	8.50B	6.85B
Investing Cash Flow	-2.58B	-3.92B	-3.26B	-1.95B	-3.81B	-6.95B
Financing Cash Flow	-5.40B	-5.46B	-3.89B	-3.14B	-11.05B	-2.50B

Hogy Medical Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5350.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3593, the sentiment is Positive. The current price of 5350 is above the 20-day moving average (MA) of 5302.00, above the 50-day MA of 5283.16, and above the 200-day MA of 4599.22, indicating a bullish trend. The MACD of 11.73 indicates Positive momentum. The RSI at 53.16 is Neutral, neither overbought nor oversold. The STOCH value of 38.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3593.

Hogy Medical Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7817	―	$192.21B	23.53	6.47%	3.11%	1.96%	22.78%
7730	―	¥144.82B	28.18	―	2.64%	5.10%	-17.80%
3154	―	¥17.83B	12.95	―	2.50%	11.12%	20.58%
7716	―	€179.19B	34.68	4.39%	2.52%	10.98%	-76.45%
3593	―	$117.07B	95.31	0.78%	1.61%	-2.06%	-79.17%
7702	―	¥10.43B	―	―	3.94%	3.36%	-310.49%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Hogy Medical Co Corporate Events

Hogy Medical Reports Decline in Financial Performance for H1 2025

Hogy Medical Co., Ltd. reported a decline in its financial performance for the six months ended September 30, 2025, with net sales decreasing by 3.9% and significant drops in operating and ordinary profits. The company’s profit attributable to owners of the parent fell by 51.4% compared to the previous year. Despite the downturn, the company plans to increase its annual dividend per share, indicating confidence in its long-term financial health. The forecast for the fiscal year ending March 31, 2026, shows a slight increase in net sales but continued pressure on profits, reflecting ongoing challenges in the market.

The most recent analyst rating on (JP:3593) stock is a Hold with a Yen5652.00 price target. To see the full list of analyst forecasts on Hogy Medical Co stock, see the JP:3593 Stock Forecast page.

Hogy Medical Revises Earnings Forecasts Amid Business Challenges

Hogy Medical Co., Ltd. has announced a downward revision of its earnings forecasts for both the interim and full fiscal year ending March 31, 2026, due to recent business performance developments. The revised forecasts indicate significant reductions in net sales, operating profit, ordinary profit, and profit attributable to owners of the parent, reflecting challenges that may impact the company’s financial health and market position.

The most recent analyst rating on (JP:3593) stock is a Hold with a Yen5652.00 price target. To see the full list of analyst forecasts on Hogy Medical Co stock, see the JP:3593 Stock Forecast page.

Hogy Medical Co. Addresses Privatization Speculation

Hogy Medical Co., Ltd. has been the subject of media reports suggesting its potential privatization, but the company has clarified that no official decision has been made. The company continues to evaluate various strategic options to enhance its corporate value, indicating ongoing considerations but no confirmed plans.

The most recent analyst rating on (JP:3593) stock is a Hold with a Yen5103.00 price target. To see the full list of analyst forecasts on Hogy Medical Co stock, see the JP:3593 Stock Forecast page.

Hogy Medical Revises Shareholder Benefits Amid Product Changes

Hogy Medical Co., Ltd. has announced a revision to its shareholder benefits program, prompted by the discontinuation of its original calendar production. The revised benefits will no longer include the original calendar but will continue to offer complimentary admission tickets to the Hoki Museum and QUO Cards, along with original design face masks. These changes will be effective for shareholders recorded as of September 30, 2025, with benefits distributed in mid-December. This adjustment reflects the company’s effort to maintain shareholder engagement and satisfaction despite changes in its product offerings.

The most recent analyst rating on (JP:3593) stock is a Hold with a Yen5103.00 price target. To see the full list of analyst forecasts on Hogy Medical Co stock, see the JP:3593 Stock Forecast page.